On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to ...
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained ...
Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion ...
Sun Pharma to acquire Organon in a $12B deal, expanding global reach and strengthening its specialty drug portfolio.
Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (“Organon”) announced that they have entered into a definitive ...
By Kashish Tandon and Rishika Sadam April 26 (Reuters) - Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co ...
After intense negotiations, Sun Pharma is set to acquire Organon for $11.75 billion, marking a significant milestone for Indian overseas acquisitions. The deal aims to strengthen Sun Pharma's global ...
Post-Organon deal, ICICI Direct downgraded Sun Pharma to Hold, IIFL adjusted to Add, Investec maintained a Sell rating, while ...
Sun Pharmaceutical Industries Ltd will acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of USD 11.75 billion in one of the largest acquisitions by Indian firms overseas.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results